

Datasheet for ABIN7164836
anti-PCSK9 antibody (AA 462-595)[Go to Product page](#)

2 Images

Overview

Quantity:	100 µL
Target:	PCSK9
Binding Specificity:	AA 462-595
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This PCSK9 antibody is un-conjugated
Application:	ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Product Details

Immunogen:	Recombinant Human Proprotein convertase subtilisin/kexin type 9 protein (462-595AA)
Isotype:	IgG
Cross-Reactivity:	Human
Purification:	>95%, Protein G purified

Target Details

Target:	PCSK9
Alternative Name:	PCSK9 (PCSK9 Products)
Background:	Background: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density

Target Details

lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed: 18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed: 18799458, PubMed: 17461796, PubMed: 18197702, PubMed: 22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed: 18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

Aliases: Convertase subtilisin/kexin type 9 preproprotein antibody, FH3 antibody, HCHOLA3 antibody, Hypercholesterolemia autosomal dominant 3 antibody, LDLCQ1 antibody, NARC 1 antibody, NARC-1 antibody, NARC1 antibody, Neural apoptosis regulated convertase 1 antibody, Neural apoptosis-regulated convertase 1 antibody, PC 9 antibody, PC9 antibody, PCSK 9 antibody, PCSK9 antibody, PCSK9_HUMAN antibody, Proprotein convertase 9 antibody, Proprotein convertase PC9 antibody, Proprotein convertase subtilisin/kexin type 9 antibody, PSEC0052 antibody, Subtilisin/kexin like protease PC9 antibody, Subtilisin/kexin-like protease PC9 antibody

UniProt: [Q8NBP7](#)

Application Details

Application Notes: Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be


Handling

handled by trained staff only.

Storage: -20 °C, -80 °C


Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Images



Immunofluorescence

Image 1. Immunofluorescence staining of HepG2 cells with ABIN7164836 at 1:100, counter-stained with DAPI. The cells were fixed in 4 % formaldehyde, permeabilized using 0.2 % Triton X-100 and blocked in 10 % normal Goat Serum. The cells were then incubated with the antibody overnight at 4 °C. The secondary antibody was Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).



Immunohistochemistry

Image 2. IHC image of ABIN7164836 diluted at 1:100 and staining in paraffin-embedded human colon cancer performed on a Leica Bond™ system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10 % normal goat serum 30 min at RT. Then primary antibody (1 % BSA) was incubated at 4 °C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.